Clinical Trials Logo

Cervical Intraepithelial Neoplasia clinical trials

View clinical trials related to Cervical Intraepithelial Neoplasia.

Filter by:

NCT ID: NCT06273553 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).

NCT ID: NCT06258564 Not yet recruiting - Recurrence Clinical Trials

The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization

Start date: May 1, 2024
Phase:
Study type: Observational

Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.

NCT ID: NCT06243666 Not yet recruiting - Cervical Cancer Clinical Trials

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Start date: February 20, 2024
Phase:
Study type: Observational

The primary objective of this study is to evaluate the protective efficacy against future infections of HPV types 16/18 or related diseases and immuno-persistence (type specific IgG antibody) of the bivalent HPV vaccine in young female populations aged 9-17 years.

NCT ID: NCT06191133 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Start date: February 1, 2024
Phase: Phase 1
Study type: Interventional

Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.

NCT ID: NCT06015854 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II

Vvax
Start date: March 23, 2021
Phase: Phase 2
Study type: Interventional

This is an open label phase II study in patients with newly diagnosed human papilloma virus type 16 (HPV16) induced cervical intraepithelial neoplasia grade 3 (CIN3). Patients will be treated with three doses of Vvax001 immunization with an interval of 3 weeks between each immunization to induce histopathological regression and HPV clearance. Regression of CIN3 lesions will be monitored using colposcopy in week 9, week 17 and week 25. When complete regression of the CIN3 lesion is observed by colposcopy, a biopsy will be taken in week 25 to confirm regression histologically. A positive histologic regression is defined as a reduction from CIN3 to CIN1 or no dysplasia. Patients with a complete regression will not undergo the standard-of-care loop excision of the transformation zone (LETZ) and will be followed-up after the study by cytology at 3, 6 and 12 months. If complete regression has not occurred by 25 weeks, a standard-of-care LETZ will be performed.

NCT ID: NCT05996796 Completed - Cervical Cancer Clinical Trials

Dry Run of the ScreenUrSelf Trial

Start date: April 10, 2023
Phase: N/A
Study type: Interventional

The proposed study is the Dry Run preceding the ScreenUrSelf trial.

NCT ID: NCT05996783 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial

ScreenUrSelf
Start date: May 25, 2023
Phase: N/A
Study type: Interventional

The goal of the ScreenUrSelf trial is to increase cervical cancer screening attendance and compliance to follow-up by offering a first-void urine self-sampling alternative to women who are currently not participating in the organized cervical cancer screening program (defined in this project as un(der)-screened women), either on the woman or her physician's personal initiative, or by responding on the invitation letter.

NCT ID: NCT05931354 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Longitudinal HPV Pap in CIN and VAIN

LHPCV
Start date: July 1, 2017
Phase:
Study type: Observational

This study will construct a longitudinal risk model of VaIN according to the HPVs distribution of cervix and vaginal for those had CIN2+. The study will include three arms to complete the follow-up data for the previous cohort constructed, and prospectively recruit new subjects with the appropriate inclusion/excluding criteria in order to increase sample size of this study.

NCT ID: NCT05851079 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions

Start date: December 10, 2021
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to compare the accuracy and sensitivity of High-throughput human papilloma virus(HPV) typing and integrated assays with routine screening protocols (Cobas HPV test combined with thinprep cytologic test(TCT) for the detection of cervical intraepithelial neoplasia in the general and hospital populations. The main questions it aims to answer are: - High-throughput HPV typing and integrated assays can screen for ≥ cervical intraepithelial neoplasia (CIN2 or CIN3) with high sensitivity and accuracy. - High-throughput HPV typing and integrated assays can be promoted as a screening tool for cervical cancer. Participants will be screened with routine screening protocols (Cobas HPV test combined with TCT test), and if the results are abnormal, colposcopy and cervical biopsy will be performed.

NCT ID: NCT05774561 Recruiting - Cervical Cancer Clinical Trials

Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.